MedTrace Logo

Value-Based Medicine (VBM) for Lung Cancer

NCT06703866 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-11-25

No results posted yet for this study

Summary

This is a prospective observational monocentric trial. The primary endpoint is the validation of predictive models. These predictive models will be used to develop a personalized clinical-functional risk profile for estimating in advance, prior to surgery, the probability for a patient to experience surgical complications, pain, fatigue, dyspnea, as well as issues related to physical function, role, social, and emotional well-being, up to 12 months post-discharge.

Conditions

Interventions

OTHER

Non Small Cell Lung Cancer (NSCLC)

Application of "value based medicine" predictive model

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Monica Casiraghi · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-27
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06703866 on ClinicalTrials.gov